

**HaemOnc. Test Request Form** 



		<b>NHS</b>
Central	&	South

Specimen(s) received (central): BMT / Slides / BMA EDTA / PB EDTA / Cyto / other Specimen(s) distribution: Histo MGG Flow

Iron WGLS Sot. WGLS Sal.

WGLS Sot. WGLS Sal.

Specimen(s) received (local):

Barcode

Referrer Information			Patient Inform	nation				
Referring consultant			Surname					
Hospital			First Name					
Department			Date of Birth			Gender		
Departmental Email (secure)			Hospital numb	er				
Telephone number / bleep			NHS number					
☐ NHS ☐ Private			Address			Postcode	:	
Diagnosis / clinical details								
Additional information	Infection Risk	⟨? Yes □ No □						
Priority	Urgent □	Cancer pathwa	y □ Routine□	Pleas	e notify the laborate	ory if clinica	illy urgent	
Sample details (see reverse for	instruction	ns)	Operator:		Tel./Bleep			
Lab reference number			Collection		Histo. macro.	UHS lak	use only	
(referrals to UHS)			date/time		UHS LAB USE			
Specimen type Refer to sample requirements overleaf.	PB □ B	BMA 🗌 BMT 🗆	l Cytogenetics □	CSF [			Other $\square$	
Please indicate if multiples of the same sample are	(EDTA) (E	EDTA)			Biopsy 🗌 Rese			
collected eg. BM √x2	☐ Trial (se	ent direct):			Biopsy Site:			
Haematology request(s) ✓				Histona	thology request(s)	/		
PB morphology  BM morph		Iron stain 🗆 B		BMT [		Congo R	ed $\square$	
- Diviniorphiciogy - Diviniorphi	ology —	iioii staiii 🗀 🗀	ivii (iiaciii) 🗆	DIVII L		Congon		
Flow cytometry test request(s)	✓ One EDTA	per sub-section						
	<u> </u>		□ Ext. T □	Dlace	na cell 🔲 🛮 Flow M			
Acute Lympho Inc. blast enumeration Progressive		Ext. B s required or known di		PidSii		way – specify	RM / DR\	
Trogressive	- Dy T pariets as	Trequired of known an			(Selia A	way - specify	DIVI / FDJ	
Wessex Genomics Laboratory Service (Southampton) test request(s) ✓ One EDTA per sub-section								
wessex Genomics Laboratory	Service (So	uthampton) test	request(s) ✓ One ED	OTA per sub	o-section			
JAK2 V617F only (Monitoring) <sup>1</sup>	Service (So	uthampton) test <i>BRAF</i> V600E	request(s) ✓ One ED	OTA per sub	MYD88 L265P			
				OTA per sub		hypermuta	□ tion * □	
JAK2 V617F only (Monitoring) <sup>1</sup>	2 🗆	BRAF V600E		OTA per sub	<i>MYD88</i> L265P			
JAK2 V617F only (Monitoring) <sup>1</sup> Post allo transplant chimerism	2	BRAF V600E FVL/PTM genot	□ yping □	OTA per sub	MYD88 L265P CLL IGHV somatic	ide lymphocyt		
JAK2 V617F only (Monitoring) <sup>1</sup> Post allo transplant chimerism BCR::ABL1 (IS) ratio monitoring BCR::ABL1 kinase domain mutat	2	BRAF V600E FVL/PTM genot	□ yping □		MYD88 L265P CLL IGHV somatic  *For IgHV, please prov	ide lymphocyt	te count:	
JAK2 V617F only (Monitoring) <sup>1</sup> Post allo transplant chimerism BCR::ABL1 (IS) ratio monitoring BCR::ABL1 kinase domain mutat Whole Genome Sequencing**	2	BRAF V600E FVL/PTM genot TKI: Acute leukaemia m	□ yping □ Start date:	RD <sup>4</sup> **	MYD88 L265P CLL IGHV somatic  *For IgHV, please provClonality	ide lymphocyt	e count:	
JAK2 V617F only (Monitoring) <sup>1</sup> Post allo transplant chimerism BCR::ABL1 (IS) ratio monitoring BCR::ABL1 kinase domain mutat Whole Genome Sequencing** Eligible tumour** presentation	2	BRAF V600E FVL/PTM genot TKI:  Acute leukaemia m AML Follow up  ALL Baseline	yping  Start date:  olecular (genetics) MR  (AML baseline from WGLS: Follow up	RD <sup>4</sup> **	MYD88 L265P CLL IGHV somatic  *For IgHV, please prov	ide lymphocyt	te count:	
JAK2 V617F only (Monitoring) <sup>1</sup> Post allo transplant chimerism BCR::ABL1 (IS) ratio monitoring BCR::ABL1 kinase domain mutat Whole Genome Sequencing** Eligible tumour** presentation Paired Germline (approx. day 1)	2	BRAF V600E FVL/PTM genot TKI:  Acute leukaemia m AML Follow up  ALL Baseline  ADULT AND TYA PATIENTS O	yping	R <b>D<sup>4</sup>**</b> Salisbury <sup>5</sup> )	MYD88 L265P CLL IGHV somatic  *For IgHV, please prov	T cell (	disease 🗆	
JAK2 V617F only (Monitoring) <sup>1</sup> Post allo transplant chimerism BCR::ABL1 (IS) ratio monitoring BCR::ABL1 kinase domain mutat Whole Genome Sequencing** Eligible tumour** presentation Paired Germline (approx. day 1) L Confirm no circulating tumound Must be confirmed before germline sample is colla	2	BRAF V600E  FVL/PTM genot  TKI:  Acute leukaemia m  AML Follow up   ALL Baseline   ADULT AND TYA PATIENTS O  Date of diagnosis/t	yping	RD <sup>4</sup> ** Salisbury <sup>5</sup> )	MYD88 L265P CLL IGHV somatic  *For IgHV, please provClonality	T cell (	disease 🗆	
Post allo transplant chimerism  BCR::ABL1 (IS) ratio monitoring  BCR::ABL1 kinase domain mutat  Whole Genome Sequencing**  Eligible tumour** presentation  Paired Germline (approx. day 1)  Confirm no circulating tumour	2	BRAF V600E  FVL/PTM genot  TKI:  Acute leukaemia m  AML Follow up   ALL Baseline  ADULT AND TYA PATIENTS O  Date of diagnosis/t  MRD Marker:  Transcript/mutatio	yping	RD <sup>4</sup> ** Salisbury <sup>s</sup> )	MYD88 L265P CLL IGHV somatic  *For IgHV, please prov	T cell (	disease 🗆	
Post allo transplant chimerism  BCR::ABL1 (IS) ratio monitoring  BCR::ABL1 kinase domain mutat  Whole Genome Sequencing**  Eligible tumour** presentation  Paired Germline (approx. day 1)  Confirm no circulating tumou  Must be confirmed before germline sample is colle  Please refer to central NHS England eligibility criteria. Ens	2	BRAF V600E  FVL/PTM genot  TKI:  Acute leukaemia m  AML Follow up   ALL Baseline  ADULT AND TYA PATIENTS O  Date of diagnosis/t  MRD Marker:  Transcript/mutatio	yping	RD <sup>4</sup> ** Salisbury <sup>s</sup> )	MYD88 L265P CLL IGHV somatic  *For IgHV, please prov	T cell (	disease 🗆	
JAK2 V617F only (Monitoring) <sup>1</sup> Post allo transplant chimerism BCR::ABL1 (IS) ratio monitoring BCR::ABL1 kinase domain mutat Whole Genome Sequencing** Eligible tumour** presentation Paired Germline (approx. day 1 L, Confirm no circulating tumous Must be confirmed before germline sample is colle Please refer to central NHS England eligibility criteria. Ensidetails are entered.	g <sup>3</sup>	BRAF V600E FVL/PTM genot  TKI:  Acute leukaemia m AML Follow up ALL Baseline ADULT AND TYA PATIENTS O Date of diagnosis/t MRD Marker: Transcript/mutatio Must be provided to ensure	yping	RD <sup>4**</sup> Salisbury <sup>5</sup> )	MYD88 L265P CLL IGHV somatic  *For IgHV, please prov  Clonality  A progressive testing strategy is use  Include histology / image	T cell (	disease 🗆	
Post allo transplant chimerism BCR::ABL1 (IS) ratio monitoring BCR::ABL1 kinase domain mutat Whole Genome Sequencing** Eligible tumour** presentation Paired Germline (approx. day 1) L Confirm no circulating tumour Must be confirmed before germline sample is colle Please refer to central NHS England eligibility criteria. Ense	2	BRAF V600E  FVL/PTM genot  TKI:  Acute leukaemia m  AML Follow up   ALL Baseline   ADULT AND TYA PATIENTS O  Date of diagnosis/t  MRD Marker:  Transcript/mutatio  Must be provided to ensure	yping	RD <sup>4</sup> ** Salisbury <sup>5</sup> ) samples for sample	MYD88 L265P CLL IGHV somatic  *For IgHV, please prov  Clonality  A progressive testing strategy is use  Include histology / implementation	T cell (	disease 🗆	
Post allo transplant chimerism  BCR::ABL1 (IS) ratio monitoring  BCR::ABL1 kinase domain mutat  Whole Genome Sequencing**  Eligible tumour** presentation  Paired Germline (approx. day 1)  L Confirm no circulating tumou  Must be confirmed before germline sample is colle  Please refer to central NHS England eligibility criteria. Ensetatilis are entered.  Wessex Genomics Laboratory  Myeloid disorders (MDS, MPN)	g <sup>3</sup>	BRAF V600E  FVL/PTM genot  TKI:  Acute leukaemia m  AML Follow up   ALL Baseline   ADULT AND TYA PATIENTS O  Date of diagnosis/t  MRD Marker:  Transcript/mutatio  Must be provided to ensure  lisbury) test required.	yping	RD <sup>4</sup> ** Salisbury <sup>5</sup> )  samples for sample	MYD88 L265P CLL IGHV somatic  *For IgHV, please prov  Clonality  A progressive testing strategy is used to be details)  details)	T cell of B cell of munophenoty	disease  disease  disease  ping report	
Please refer to central NHS England eligibility criteria. Ensemble are entered.  JAK2 V617F only (Monitoring)  Post allo transplant chimerism  BCR::ABL1 (IS) ratio monitoring  BCR::ABL1 kinase domain mutat  Whole Genome Sequencing**  Eligible tumour** presentation  Paired Germline (approx. day 1)  Confirm no circulating tumour  Must be confirmed before germline sample is collepted in the confirmed before germline (MDS, MPN).  Wessex Genomics Laboratory States in the confirmed before germline (MDS, MPN).	g <sup>3</sup>	BRAF V600E  FVL/PTM genot  TKI:  Acute leukaemia m  AML Follow up   ALL Baseline   ADULT AND TYA PATIENTS OF  Date of diagnosis/t  MRD Marker:  Transcript/mutatio  Must be provided to ensure  lisbury) test requ  L3,#)  Myelo	yping	RD <sup>4</sup> ** Salisbury <sup>5</sup> ) samples for sample	MYD88 L265P CLL IGHV somatic  *For IgHV, please prov  Clonality  A progressive testing strategy is used to be details)  details)	T cell (	disease  disease  disease  ping report	
Post allo transplant chimerism  BCR::ABL1 (IS) ratio monitoring  BCR::ABL1 kinase domain mutat  Whole Genome Sequencing**  Eligible tumour** presentation  Paired Germline (approx. day 1)  L Confirm no circulating tumou  Must be confirmed before germline sample is colle  Please refer to central NHS England eligibility criteria. Ensetatilis are entered.  Wessex Genomics Laboratory  Myeloid disorders (MDS, MPN)	g <sup>3</sup>	BRAF V600E  FVL/PTM genot  TKI:  Acute leukaemia m  AML Follow up   ALL Baseline   ADULT AND TYA PATIENTS OF  Date of diagnosis/t  MRD Marker:  Transcript/mutatio  Must be provided to ensure  lisbury) test requ  L3,#)  Myelo	yping	RD <sup>4**</sup> Salisbury <sup>5</sup> )  for samples  ALL (T-G-band	MYD88 L265P CLL IGHV somatic  *For IgHV, please prov  Clonality  A progressive testing strategy is used to be details)  details)	T cell of the search of the se	disease  disease  disease  ping report	
Please refer to central NHS England eligibility criteria. Ensertials are entered.  Wessex Genomics Laboratory Stable in discount of the Myeloid disorders (MDS, MPN G-banding	g <sup>3</sup>	BRAF V600E  FVL/PTM genot  TKI:  Acute leukaemia m  AML Follow up   ALL Baseline   ADULT AND TYA PATIENTS OF  Date of diagnosis/t  MRD Marker:  Transcript/mutatio  Must be provided to ensure  lisbury) test requ  L3,#)  Myelo	yping	RD <sup>4**</sup> Salisbury <sup>5</sup> )  for samples  ALL (T-G-band	MYD88 L265P CLL IGHV somatic  *For IgHV, please prov  Clonality  A progressive testing strategy is used to details)  and B-) ding	T cell of the search of the se	disease  disease  disease  ping report	
JAK2 V617F only (Monitoring)  Post allo transplant chimerism  BCR::ABL1 (IS) ratio monitoring  BCR::ABL1 kinase domain mutat  Whole Genome Sequencing**  Eligible tumour** presentation  Paired Germline (approx. day 1)  Confirm no circulating tumou  Must be confirmed before germline sample is colle  Please refer to central NHS England eligibility criteria. Ens  details are entered.  Wessex Genomics Laboratory  Myeloid disorders (MDS, MPN  G-banding	g³	BRAF V600E  FVL/PTM genot  TKI:  Acute leukaemia m  AML Follow up   ALL Baseline   ADULT AND TYA PATIENTS OF  Date of diagnosis/t  MRD Marker:  Transcript/mutatio  Must be provided to ensure  lisbury) test required  L3,#)  Myelo  id NGS panel	yping	Salisbury <sup>5</sup> ) Salisbury <sup>5</sup> ) for samples ALL (T- G-band Lymph	MYD88 L265P CLL IGHV somatic  *For IgHV, please prov	T cell of the second se	disease  disease  disease  ping report	
Please refer to central NHS England eligibility criteria. Ensertials are entered.  Wessex Genomics Laboratory Superior of Myeloid disorders (MDS, MPN) G-banding Genome Sequencing The Season of a Clinical indicate the AML FLT3-ITD FLT3-TKD Free Presentation (Month of the Confirmation of	g³	BRAF V600E  FVL/PTM genot  TKI:  Acute leukaemia m  AML Follow up   ALL Baseline   Date of diagnosis/t  MRD Marker:  Transcript/mutatio  Must be provided to ensure  L3,#)  Myelo  id NGS panel  IDH1/IDH2  ms with Eosinophilia	yping	RD <sup>4**</sup> Salisbury <sup>5</sup> )  for sample  ALL (T- G-band Lymph FISH Myelo	MYD88 L265P CLL IGHV somatic  *For IgHV, please prov	T cell of the second se	disease  disease  disease  ping report  ray   cing	
Please refer to central NHS England eligibility criteria. Ensertials are entered.  Wessex Genomics Laboratory Separation of AML  FLT3-ITD FLT3-TKD  Post allo transplant chimerism of Monitoring BCR::ABL1 (IS) ratio monitoring BCR::ABL1 kinase domain mutation of Monitoring Sequencing**  Eligible tumour** presentation Paired Germline (approx. day 1 of Light Confirm no circulating tumous Must be confirmed before germline sample is college of Monitoring Sequence of Must be confirmed before germline sample is college of Must be confirmed before germline sample	2	BRAF V600E  FVL/PTM genot  TKI:  Acute leukaemia m  AML Follow up   ALL Baseline   Date of diagnosis/t  MRD Marker:  Transcript/mutatio  Must be provided to ensure  L3,#)  Myelo  id NGS panel  IDH1/IDH2  ms with Eosinophilia	yping	for sample  ALL (T- G-bance Lymph FISH Myelo CD138	MYD88 L265P CLL IGHV somatic  *For IgHV, please prov	T cell of the second se	disease  disease  disease  ping report  ray   cing	
Please refer to central NHS England eligibility criteria. Ensertials are entered.  Wessex Genomics Laboratory Separation of AML  FLT3-ITD FLT3-TKD  Post allo transplant chimerism of Monitoring BCR::ABL1 (IS) ratio monitoring BCR::ABL1 kinase domain mutation of Monitoring Sequencing**  Eligible tumour** presentation Paired Germline (approx. day 1 of Light Confirm no circulating tumous Must be confirmed before germline sample is college of Monitoring Sequence of Must be confirmed before germline sample is college of Must be confirmed before germline sample	g³	BRAF V600E  FVL/PTM genot  TKI:  Acute leukaemia m  AML Follow up   ALL Baseline   ADULT AND TYA PATIENTS O  Date of diagnosis/t  MRD Marker:  Transcript/mutatio  Must be provided to ensure  lisbury) test requ  L3,#)  Myelo  id NGS panel  IDH1/IDH2  ms with Eosinophilia  exon 12) (all diagnosis  CIT NGS panel (if I	yping	for sample  ALL (T- G-bance Lymph FISH Myelo CD138	MYD88 L265P CLL IGHV somatic  *For IgHV, please prov  Clonality  A progressive testing strategy is used to details)  and B-) ding	T cell of the second se	disease  disease  disease  ping report  ray   cing	
Please refer to central NHS England eligibility criteria. Ensemble are entered.  Wessex Genomics Laboratory Septembles are entered.	g³	BRAF V600E  FVL/PTM genot  TKI:  Acute leukaemia m  AML Follow up   ALL Baseline   ADULT AND TYA PATIENTS O  Date of diagnosis/t  MRD Marker:  Transcript/mutatio  Must be provided to ensure  lisbury) test requ  L3,#)  Myelo  id NGS panel  IDH1/IDH2  ms with Eosinophilia  exon 12) (all diagnosis  CIT NGS panel (if I	yping	for sample  ALL (T- G-bance Lymph FISH Myelo CD138	MYD88 L265P CLL IGHV somatic  *For IgHV, please prov  Clonality  A progressive testing strategy is used to details)  and B-) ding	T cell of the second se	disease  disease  disease  ping report  ray   cing	
Please refer to central NHS England eligibility criteria. Ensertables are entered.  Wessex Genomics Laboratory September 2. Myeloid disorders (MDS, MPN) G-banding Geback Chronic phase is not a clinical indice.  MPN (including Myeloid/Lymph MPN gene panel (JAK2 V617F/CAL) KIT D816V	g³	BRAF V600E  FVL/PTM genot  TKI:  Acute leukaemia m  AML Follow up   ALL Baseline   ADULT AND TYA PATIENTS O  Date of diagnosis/t  MRD Marker:  Transcript/mutatio  Must be provided to ensure  lisbury) test requ  L3,#)  Myelo  id NGS panel  IDH1/IDH2  ms with Eosinophilia  exon 12) (all diagnosis  CIT NGS panel (if I	yping	for sample  ALL (T- G-bance Lymph FISH Myelo CD138	MYD88 L265P CLL IGHV somatic  *For IgHV, please prov  Clonality  A progressive testing strategy is used to details)  and B-) ding	T cell of B cell of munophenoty  SNP are  HL, etc.)  253 sequence  only (storage)	disease  disease  disease  ping report  ray   cing	

Email / phone

## Sample transport

The referring laboratory is responsible for the safe transfer of tissue and it is thus recommended that Royal Mail Recorded Delivery or an equivalent tracked postal service is used.

Transport tracking ID

Please send flow samples to:	WGLS (Southampton) samples to:	WGLS (Salisbury) samples to:	BMT samples to:
Department of Immunology Laboratory Medicine University Hospital Southampton NHFT, Tremona Road, Southampton, Hampshire, SO16 6YD.	Formerly Department of Molecular Pathology Duthie Link Building, Mailpoint 225, University Hospital Southampton NHSFT, Tremona Road, Southampton, Hampshire, SO16 6YD.	Formerly Wessex Regional Genetics Laboratory Salisbury District Hospital, Salisbury, Wiltshire, SP2 8BJ	Department of Cellular Pathology, Pathology Block, Level E, Mailpoint 002. University Hospital Southampton NHSFT, Tremona Road, Southampton, Hampshire, SO16 6YD.
☎ 02381 206615 / 02381 206640 ☐ immunologylab@uhs.nhs.uk		■ 01722 429080  shc-tr.WRGLdutyscientist@nhs.net  www.wrgl.org.uk	<b>☎</b> 023 8120 4879 <b>☐</b> cellpath@uhs.nhs.uk
UKAS ref: 8696	UKAS ref: 9194	UKAS ref: 1175	UKAS Ref: 8178

## **Sample requirements**

Details on both the referral card and the sample tube should be complete and legible. A minimum of 3 ID points are required. We reserve the right to refuse to process samples with incomplete, illegible or ambiguous patient information. Any samples in the wrong tube or medium, or which are subject to significant delay in transit, are liable to be rejected.

Flow cytometry

WGLS (Southampton) Formerly Molecular Pathology EDTA whole blood, bone marrow or fluid in universal container.

Sample must arrive and be tested within 72 hours of collection

**FFPE:** Send FFPE block (preferred) or tissue scrolls (3 x  $20\mu m$ ). Scrolls should be prepared on a clean microtome, ideally using a fresh blade per case, to avoid the risk of cross-contamination.

PB: Send minimum 3.4ml EDTA as an independent sample. This must not have been used previously on an automated laboratory analyser.

- <sup>1</sup> JAK2 V617F only requested for **monitoring** of known JAK2 V617F variant allele frequency only. <u>All referrals for suspected/confirmed MPN should go for MPN gene panel at WGLS (Salisbury).</u>
- 2 This laboratory performs whole PB/BM chimerism. This is not requesting Lineage Specific Chimerism, which is sent directly from clinical teams.
- <sup>3</sup> BCR::ABL1 (IS) ratio monitoring for CML/TKI monitoring only. For all ?CML or confirmed CML diagnostic referrals, send PB/BM sample for FISH/G-banding at WGLS (Salisbury) (see Myeloid disorders section of the form). For BCR::ABL1 (IS) ratio monitoring, if PB sample, please send minimum 12ml EDTA.
- <sup>4</sup> For MRD analysis on PB, please send 20ml EDTA; if BM, please send 5ml EDTA. Patients monitored at unusual laboratories must be highlighted and the MRD lab identified.
- <sup>5</sup> For AML cases where the diagnostic sample identifies a molecular MRD marker as part of the genetic work up, material from the baseline sample is standardly sent from the WGLS Salisbury (the standard cytogenetics sample <u>no additional sample required specifically for AML baseline MRD</u>) to WGLS Southampton for onward sending to the relevant laboratory.

<sup>6</sup>Adult patients (>26 years of age), TYA patients (16-25 years of age) only. Paediatric patients remain under the care of the CNS/trials team(s). Samples for RNA extraction must arrive in this laboratory within 48 hours of collection.

\*\* This is a send away test.

## RM:

- Conventional cytogenetics for acute leukaemias, MDS, MPD and aplastic anaemia: 1-2ml in heparinised transport medium or lithium heparin.
- For new paediatric acute leukaemias: 1-2ml in heparinised transport medium or lithium heparin + KCH (3 drops of BM in KCH to be fixed at referring laboratory).
- Molecular studies of FLT3-ITD, FLT3-TKD, NPM1, IDH1, IDH2, TP53, KIT, JAK2, JAK2 exon 12, CALR, MPL and Myeloid NGS panel: 2-3ml in EDTA; however, material sent in BM heparinised transport medium or lithium heparin is acceptable.

## PB:

- Conventional cytogenetics for new diagnosis CML, myelofibrosis or new acute leukaemias if no BM available: 5-10ml in lithium heparin.
- FISH for CLL/MCL and TP53 mutation testing: 5-10ml in lithium heparin.
- Molecular studies of JAK2, CALR, MPL, myeloid NGS panel, etc.: 5-10ml in EDTA.
- FIP1L1::PDGFRA: 10ml in EDTA.

Smears: for CLL or NHL with suitable FISH markers, FISH can be attempted on freshly made, unfixed, unstained smears (at least 4 smears) if no fresh material is available. Please note that FISH can be attempted on smears that have been stored for some time if no other material available. Biopsies: FFPE sections / tumour dabs: slides containing unstained FFPE sections (3-4µm) or tumour dabs should contain at least 2 patient

identifiers. Please package in a slide box. For large FFPE sections, please also send H&E slide with the tumour area appropriately marked.

**Other Tissues:** lymph node, spleen, skin etc. should be sent in transport medium upon previous discussion with the laboratory.

<u>Please phone as soon as possible if anything is sent by courier which might arrive outside normal working hours.</u>

There is an on-call rota for acute

presentations and Burkitt lymphoma after hours on a Friday or at the weekend (please phone the switch board on 01722 336262).

In submitting samples, the clinician confirms that consent has been obtained for testing and storage. Anonymised stored samples may be used for quality control procedures including validation of new genetic tests.

Cellular Pathology Specimen to be submitted in 60ml pot containing 10% neutral buffered formalin (ratio of 10:1). Direct purchase from Genta Medical.